Business Context and Reporting Period
This Form 8-K, dated September 30, 2020, is a current report filed by Analog Devices, Inc. (ADI) regarding "Other Events" (Item 8.01). The filing provides supplemental disclosures to the Definitive Proxy Statement for the proposed acquisition of Maxim Integrated Products, Inc. (Maxim). The disclosures were made to address allegations in multiple shareholder lawsuits challenging the merger, specifically concerning omitted material information regarding the transaction's background, financial advisor opinions, and valuation methodologies.
Key Financial Metrics and Valuation Data
The filing does not report ADI's actual quarterly revenue, profit, or cash flow for the period ended September 30, 2020. Instead, it discloses financial projections and valuation multiples used by financial advisors (Morgan Stanley, BofA Securities, and J.P. Morgan) to support the merger.
- Valuation Multiples (CY2021 Estimates):
- ADI: EV/EBITDA 19.1x; P/E 23.8x (Morgan Stanley); EV/EBITDA 19.8x; P/E 24.2x (BofA).
- Maxim: EV/EBITDA 18.8x; P/E 26.0x (Morgan Stanley); EV/EBITDA 18.8x; P/E 26.9x (BofA).
- Street Case Projections (ADI - CY2020E): Revenue $5,306 million; EBITDA $2,418 million; EPS $4.33.
- Street Case Projections (Maxim - CY2020E): Revenue $2,105 million; EBITDA $731 million; EPS $2.11.
- Balance Sheet Items Used in Valuation:
- Maxim estimated net cash balance: $641 million (as of June 30, 2020).
- ADI net debt balance: $4.8 billion (as of May 2, 2020).
- DCF Assumptions: Terminal growth rates of 2.5% to 3.5%; Discount rates of 8.25% to 10.25%.
Material Changes and Disclosures
The filing amends and supplements the Definitive Proxy Statement with the following material details previously alleged to be omitted:
- Transaction Timeline: Clarified that the ADI M&A subcommittee met on February 17, 2020, to discuss potential targets including Maxim, and met again on April 22, 2020, to discuss transaction terms.
- Competitive Process: Disclosed that Maxim's board authorized communication to "Company B" (a potential suitor) that Maxim was not interested in a transaction at that time. Following this, Company B made no further proposals, and no confidentiality or standstill agreements were entered into.
- Financial Advisors: Explained that ADI engaged BofA Securities as a second independent financial advisor due to the transaction's size and significance, citing BofA's reputation and industry experience.
- Valuation Methodology: Provided specific details on the "Street Case" financial projections used by Morgan Stanley and the specific peer groups and multiples used by BofA Securities and J.P. Morgan.
- Projection Details: Added rows for Depreciation, Capital Expenditure, and Change in Net Working Capital to the summary of projections for both ADI and Maxim through fiscal year 2029.
Guidance, Risks, and Contingencies
Legal Contingencies: The filing details eight active lawsuits (seven federal, one state) filed by purported shareholders of Maxim and ADI. Plaintiffs allege violations of the Securities Exchange Act and breach of fiduciary duty, seeking to enjoin the merger or obtain rescissionary damages. ADI and Maxim deny all allegations.
Forward-Looking Risks: Management highlights significant uncertainties that could cause actual results to differ from projections, including:
- Duration and impact of the COVID-19 pandemic.
- Global economic conditions and credit market stability.
- Supply chain constraints (raw materials, manufacturing capacity).
- Regulatory approval risks and potential conditions.
- Integration risks and the ability to achieve anticipated synergies.
- Retention of key personnel.
Management Commentary: The company states these disclosures are made solely to moot the allegations in the complaints and do not admit that the information is material or required by law.
Investor Verification Checklist
- Verify the status of the shareholder lawsuits (e.g., Shiva Stein v. Maxim, Coe Living Trust v. ADI) and whether they have been stayed or dismissed.
- Confirm the final vote results of the ADI shareholder meeting scheduled for October 8, 2020.
- Review the definitive joint proxy statement/prospectus for the complete list of risk factors and the full text of the Merger Agreement.
- Monitor regulatory filings for any conditions imposed by antitrust authorities on the ADI-Maxim combination.
- Compare the disclosed "Street Case" projections against actual consensus estimates at the time of the merger closing.